| Autor: |
George L Bakris, Peter Rossing, Stefan D Anker, Gerasimos Filippatos, Bertram Pitt, Shweta Bansal, Maria E F Canziani, Rita Birne, Luis M Ruilope, Alfredo E Farjat, Peter Kolkhof, Andrea Lage, Meike Brinker |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
BMJ Open, Vol 14, Iss 3 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2044-6055 |
| DOI: |
10.1136/bmjopen-2023-076444 |
| Popis: |
Objectives This study aimed to evaluate the efficacy and safety of finerenone, a selective, non-steroidal mineralocorticoid receptor antagonist, on cardiovascular and kidney outcomes by age and/or sex.Design FIDELITY post hoc analysis; median follow-up of 3 years.Setting FIDELITY: a prespecified analysis of the FIDELIO-DKD and FIGARO-DKD trials.Participants Adults with type 2 diabetes and chronic kidney disease receiving optimised renin–angiotensin system inhibitors (N=13 026).Interventions Randomised 1:1; finerenone or placebo.Primary and secondary outcome measures Cardiovascular (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or hospitalisation for heart failure (HHF)) and kidney (kidney failure, sustained ≥57% estimated glomerular filtration rate (eGFR) decline or renal death) composite outcomes.Results Mean age was 64.8 years; 45.2%, 40.1% and 14.7% were aged |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
